ANRO (Alto Neuroscience) Long-Term Debt: $16.22 Mil (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $24.78
! 1 Warning Sign
View Full Analysis

What is Alto Neuroscience Long-Term Debt?

Alto Neuroscience ANRO -0.64% 12 Long-Term Debt is $16.22 Mil as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Alto Neuroscience's Long-Term Debt for the quarter that ended in Mar. 2026 was $16.22 Mil.

Alto Neuroscience's quarterly Long-Term Debt declined from Sep. 2025 ($22.44 Mil) to Dec. 2025 ($18.40 Mil) and declined from Dec. 2025 ($18.40 Mil) to Mar. 2026 ($16.22 Mil).

Alto Neuroscience's annual Long-Term Debt increased from Dec. 2023 ($9.86 Mil) to Dec. 2024 ($11.56 Mil) and increased from Dec. 2024 ($11.56 Mil) to Dec. 2025 ($18.40 Mil).

Alto Neuroscience  (NYSE:ANRO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Alto Neuroscience Long-Term Debt Related Terms

Alto Neuroscience Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Long-Term Debt Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 9.47 9.86 11.56 18.40

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.15 22.12 22.44 18.40 16.22
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $16.22 Mil mean?
Alto Neuroscience (ANRO) has a Long-Term Debt of $16.22 Mil as of Mar. 2026.
Is Alto Neuroscience's Long-Term Debt too high?
Alto Neuroscience's current Long-Term Debt is $16.22 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Long-Term Debt compare to SANA and AVTX?
Alto Neuroscience's Long-Term Debt of $16.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Alto Neuroscience's current Long-Term Debt is $16.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Long-Term Debt of $16.22 Mil. The current Long-Term Debt is $16.22 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Long-Term Debt is $16.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.78
Price